You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma

  • Technology appraisal guidance
  • Reference number: TA268
  • Published:  12 December 2012
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Melanoma (stage III or IV) - ipilimumab: appendix A - matrix of stakeholders

Melanoma (stage III or IV) - ipilimumab: appendix A - matrix of stakeholders Melanoma (stage III or IV) - ipilimumab: appendix A - matrix of stakeholders
02 January 2015
(99.35 Kb 28 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 08 January 2015

Back to top